Drug
Efatutazone clinical trials
Also written CS-7017.
- studies test it
- 12
- open now
- 0
- in phase 3
- 0
- first study started
- 2006
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2009 (3)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2008 | 2 |
| 2009 | 3 |
| 2010 | 3 |
| 2011 | 1 |
| 2014 | 1 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 3
Daiichi Sankyo (7) · Alliance for Clinical Trials in Oncology (2) · Daiichi Sankyo Co., Ltd. (2) · Georgetown University (1)
Often tested with
Tested in the same studies.
Paclitaxel (3) · Erlotinib (1) · Carboplatin (1) · Bexarotene (1)
Studies
Open first, then newest update. How each study uses efatutazone is read from its arms, and is right about nine times in ten.
Testing it · 12
- Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by SurgeryCompletedPhase 2Alliance for Clinical Trials in OncologyNCT02249949Written as efatutazone
- Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid CancerCompletedPhase 2Alliance for Clinical Trials in OncologyNCT02152137Written as efatutazone
- CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)CompletedPhase 1Daiichi Sankyo Co., Ltd.NCT01199068Written as CS-7017
- Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line ChemotherapyTerminatedPhase 2Daiichi SankyoNCT00986440Written as CS-7017
- Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Participants With Advanced or Metastatic CancerCompletedPhase 1Daiichi SankyoNCT00408434Written as CS-7017
- Extended Use Protocol for Participants With Cancer to Receive Continued Treatment With CS-7017CompletedPhase 1Daiichi SankyoNCT00881569Written as CS-7017
- A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With PaclitaxelTerminatedPhase 1/2Daiichi SankyoNCT00603941Written as CS-7017
- CS-7017 in Combination With Carboplatin/Paclitaxel in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)CompletedPhase 1Daiichi Sankyo Co., Ltd.NCT01199055Written as CS-7017
- Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung CancerCompletedPhase 2Daiichi SankyoNCT01101334Written as CS-7017
- Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung CancerCompletedPhase 2Daiichi SankyoNCT00806286Written as CS7017 tablets
- Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line TherapyCompletedPhase 2Daiichi SankyoNCT00967616Written as CS7017
- Phase I Study of CS-7017 and BexaroteneTerminatedPhase 1Georgetown UniversityNCT01504490Written as CS-7017 and Bexarotene
Codes
What other systems call efatutazone · ClinicalTrials.gg INT004912
- MeSH (NLM) C510342efatutazoneConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) M17ILL71MCEFATUTAZONEConfirmed FDA, NLM, Wikidata
- Wikidata Q21083321efatutazoneConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C83819EfatutazoneOne source FDA
- DrugBank DB11894One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C510342 | efatutazone | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | M17ILL71MC | EFATUTAZONE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q21083321 | efatutazone | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C83819 | Efatutazone | One source FDA |
| DrugBank | DB11894 | — | One source Wikidata |
Also registered as efatutazone dihydrochloride (UNII 76B44WEA8O).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.